Identification and Description of Patients With High-risk Non Metastatic RCC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorośli pacjenci z diagnozą raka nerki ograniczonego do nerki lub wysokiego ryzyka miejscowo zaawansowanego
- •Włączeni do rejestru UroCCR między 1 stycznia 2014 a 31 grudnia 2023
- •Wyrażenie zgody na uczestnictwo w rejestrach UroCCR i UroCCR-Chain
✗ Disqualifies
- •Pacjenci z przerzutami nowotworu w momencie włączenia do badania
- •Pacjenci, których danych nie można połączyć między rejestrami UroCCR i SNDS
- •Pacjenci z dziedzicznym rakiem nerki
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
CHU Bordeaux
Bordeaux, France
Trial contact
Jean-Christophe BERNHARD, Pr
Gaelle MARGUE, Dr
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.